May 13, 2020 / 8:58 PM / 17 days ago

BRIEF-Ultragenyx Announces Positive Longer-Term Results From First Three Cohorts Of Phase 1/2 Study Of DTX301 Gene Therapy

May 13 (Reuters) - Ultragenyx Pharmaceutical Inc:

* ULTRAGENYX ANNOUNCES POSITIVE LONGER-TERM RESULTS FROM FIRST THREE COHORTS OF PHASE 1/2 STUDY OF DTX301 GENE THERAPY IN ORNITHINE TRANSCARBAMYLASE (OTC) DEFICIENCY

* ULTRAGENYX PHARMACEUTICAL INC - COHORT 3 DOSE HAS BEEN SELECTED FOR PHASE 3 STUDY, WHICH IS CURRENTLY EXPECTED TO INITIATE IN FIRST HALF OF 2021

* ULTRAGENYX PHARMACEUTICAL - DOSING IN 4TH COHORT PATIENTS AT COHORT 3 DOSE IS CURRENTLY ON HOLD DUE TO COVID-19, DATA EXPECTED IN H2 2020 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below